Department of Ophthalmology, School of Medicine, University of Missouri-Columbia, Columbia, MO 65212, USA.
Charles W. Gehrke Proteomics Center, Department of Biochemistry, University of Missouri-Columbia, Columbia, MO 65211, USA.
Int J Mol Sci. 2022 Jan 20;23(3):1099. doi: 10.3390/ijms23031099.
Smaller oligomeric chaperones of α-crystallins (αA- and αB-) have received increasing attention due to their improved therapeutic potential in preventing protein aggregating diseases. Our previous study suggested that deleting 54-61 residues from the N-terminal domain (NTD) of αB-crystallin (αBΔ54-61) decreases the oligomer size and increases the chaperone function. Several studies have also suggested that NTD plays a significant role in protein oligomerization and chaperone function. The current study was undertaken to assess the effect of deleting conserved 21-28 residues from the activated αBΔ54-61 (to get αBΔ21-28, Δ54-61) on the structure-function of recombinant αBΔ21-28, Δ54-61. The αBΔ21-28, Δ54-61 mutant shows an 80% reduction in oligomer size and 3- to 25-fold increases in chaperone activity against model substrates when compared to αB-WT. Additionally, the αB∆21-28, ∆54-61 was found to prevent β-amyloid (Aβ) fibril formation in vitro and suppressed Aβ-induced cytotoxicity in ARPE-19 cells in a more effective manner than seen with αB-WT or αB∆54-61. Cytotoxicity and reactive oxygen species (ROS) detection studies with sodium iodate (SI) showed that the double mutant protein has higher anti-apoptotic and anti-oxidative activities than the wild-type or αB∆54-61 in oxidatively stressed cells. Our study shows that the residues 21-28 and 54-61 in αB-crystallin contribute to the oligomerization and modulate chaperone function. The deletion of conserved 21-28 residues further potentiates the activated αBΔ54-61. We propose that increased substrate affinity, altered subunit structure, and assembly leading to smaller oligomers could be the causative factors for the increased chaperone activity of αBΔ21-28, Δ54-61.
由于小分子寡聚伴侣在预防蛋白聚集疾病方面具有更好的治疗潜力,因此越来越受到关注。我们之前的研究表明,从αB 晶体蛋白(αB)的 N 端结构域(NTD)中删除 54-61 个残基(αBΔ54-61)可减小寡聚物的大小并增加伴侣的功能。有几项研究还表明,NTD 在蛋白质寡聚化和伴侣功能中起着重要作用。目前的研究旨在评估从激活的αBΔ54-61 中删除保守的 21-28 个残基(得到αBΔ21-28,Δ54-61)对重组αBΔ21-28,Δ54-61 的结构-功能的影响。与αB-WT 相比,αBΔ21-28,Δ54-61 突变体的寡聚体大小减少了 80%,对模型底物的伴侣活性增加了 3-25 倍。此外,与αB-WT 或αBΔ54-61 相比,αB∆21-28,∆54-61 可在体外抑制β-淀粉样蛋白(Aβ)纤维形成并抑制 ARPE-19 细胞中的 Aβ 诱导的细胞毒性。用碘酸钠(SI)进行的细胞毒性和活性氧(ROS)检测研究表明,与野生型或αBΔ54-61 相比,双突变体蛋白在氧化应激细胞中具有更高的抗凋亡和抗氧化活性。我们的研究表明,αB 晶体蛋白中的残基 21-28 和 54-61 有助于寡聚化并调节伴侣的功能。删除保守的 21-28 个残基进一步增强了激活的αBΔ54-61。我们提出,增加的底物亲和力、改变的亚基结构和导致较小寡聚物的组装可能是导致αBΔ21-28,Δ54-61 伴侣活性增加的原因。